阿尔茨海默病（俗称"老年痴呆症"）的治疗是一项世界性难题，但全球医学界的探索从未止步。日前， 国内最大规模阿尔茨海默病注册研究正式开启。 在今日公告中，万邦德还指出，石杉碱甲是用于改善认知功能的胆碱酯酶抑制剂，临床前研究展现出延 缓阿尔茨海默病疾病进展的潜力及广泛的综合获益，包括对β淀粉样蛋白的降低作用，抗炎、抗氧化应 激以及神经元保护作用，有望成为具有广谱抗阿尔茨海默病型痴呆的药物。 据了解，石杉碱甲控释片是万邦德自主研发的用于治疗轻、中度阿尔茨海默病型痴呆的2.2类新药，采 用双相控释技术，平缓药物释放峰谷曲线，并延长药物体内释放时间，从而实现快速起效，减少不良反 应，提升给药剂量与良好的安全性。同时，控释技术支持每天一次给药，提高患者的用药便利性和长期 依从性。 另外，万邦德还表示，此次开展的II/III期临床研究，是中国目前已知规模最大的阿尔茨海默病注册研 究。公司积极推进受试者入组，公司将继续与首都医科大学宣武医院等全国50多家研究机构紧密合作， 进一步验证药物的安全性、有效性，为产品的最终上市申请提供关键数据支撑。 据悉，万邦德办公地浙江台州，是我国原料药的生产重地，涌现出了一批知名药企。其中，万 ...

Core Insights - The company Wanbangde is making significant progress in the development of new drugs for Alzheimer's disease, particularly with its controlled-release tablet of Huperzine A (FN12), which is currently in the II/III phase of clinical trials [1][2] - The drug has shown promising safety and efficacy results, with the potential to improve cognitive function in patients [1] - Wanbangde is also expanding its product portfolio in the peptide drug sector, focusing on new compounds that target various mechanisms, including those related to Alzheimer's disease [3] Group 1: Alzheimer's Disease Drug Development - Wanbangde has been dedicated to Alzheimer's disease drug research for many years, aiming to develop new treatment options for patients globally [1] - The controlled-release tablet of Huperzine A is part of the largest known Alzheimer's disease registration study in China, with collaboration from over 50 research institutions [2] - Preliminary studies indicate that Huperzine A can significantly enhance cognitive function and has multiple beneficial effects, including anti-inflammatory and neuroprotective properties [1][2] Group 2: Peptide Drug Research - The company is developing a new class of peptide drugs that have shown excellent results in preclinical animal studies, including weight loss and improvements in diabetes-related metrics [3] - The peptide drugs have received orphan drug designation from the FDA, indicating their potential for treating rare diseases [3] - Wanbangde is also exploring new targets and mechanisms for Alzheimer's disease treatment through its peptide drug research, aiming to establish a strong position in the global Alzheimer's drug development landscape [3]

Core Viewpoint - Wanbangde's subsidiary has initiated a critical II/III phase clinical trial for its new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease, marking a significant step in the company's research and development efforts [1][3]. Group 1: Clinical Trial and Drug Development - The clinical trial for Huperzine A controlled-release tablets is the largest known Alzheimer's disease registration study in China, employing a multi-center, randomized, double-blind design with placebo and positive drug controls [1][3]. - Huperzine A is a cholinesterase inhibitor that has shown potential in preclinical studies to delay the progression of Alzheimer's disease, with benefits including reduction of β-amyloid protein, anti-inflammatory, antioxidant effects, and neuroprotection [1][3]. - The controlled-release technology used in Huperzine A tablets allows for a smoother drug release profile, enhancing patient compliance with once-daily dosing and improving safety [1][2]. Group 2: Financial Performance and Market Position - In the first half of 2025, the company reported a revenue of 579 million yuan, a decrease of 23.15% year-on-year, and a net profit of 13.46 million yuan, down 64.29% year-on-year [2]. - Huperzine A injection, a first-line treatment for memory disorders, holds a market share of 24.37%, ranking second in the Huperzine A formulation market [2]. - The company is recognized for its technological authority and market exclusivity, being the sole manufacturer of Huperzine A injection and participating in the formulation of industry standards [2]. Group 3: Research Collaboration and Future Prospects - The company collaborates with over 50 research institutions, including Capital Medical University Xuanwu Hospital, to validate the safety and efficacy of Huperzine A controlled-release tablets, providing critical data for future market applications [3]. - The clinical trial will also explore Aβ-PET imaging to observe changes in amyloid protein deposition, further validating the drug's potential to delay disease progression [3].